Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028 Report Overview:
Controlled release drug mechanism has provided novel delivery platform that can be optimized, thus resulting in the generation of a robust, strong and impressive pipeline of the controlled release drugs for the broad-spectrum diseases like cancer, infectious diseases, autoimmune diseases, inflammatory diseases and neurological affections. Already available controlled release drugs categorized under tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) or glucagon-like peptide-1 (GLP-1) analogues for diabetes have been completely revolutionizing the pharmaceutical market by increasing the survival rate of the patients and who have been receiving major toxicity and side-effects due to unwanted concentration of the drug inside the body.
The efforts involved in the development of the market and associated parameters have helped the market to deliver promising results, thus, making the controlled release mechanism as one of the widely accepted and appreciated drug delivery system. Drug developers are now adopting to controlled release mechanism of delivering the drug in order to push the sales of the new as well existing drugs for key indications. Also, diminished side effects, reduced toxicity and maximum precision are some of the factors with which controlled release drugs are getting continuous level of acceptance from the researchers as well as the patients. It is estimated that the advent of control release technology as an important supportive technology in therapeutics sector is shaping the market towards success which researchers and patients were in need for a long period of time.
As per Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028 report findings, the arrival of the respective drug delivery market has brought a fundamental change and transformation shift in the pharmaceutical sector as it has slated every limits that were there in the previous markets which were leading to the development of unwanted side-effects in the patients. The market is also attracting several novel patients as the wide applications received by the older patients are expected to increase the bars of the markets with respect to advantages and benefits. Through the analysis of the market, it can be observed that development of safe as well as effective controlled release drugs by the researchers and the clinicians is estimated to provide the market specific pharmacotherapeutic regimens, leading to wide-adoption of the market. Furthermore, the robust clinical pipeline of the market and its impact on delivering the desired concentration of the drug is suggesting high-end future growth in every indication. It is believed that the market will soon explore the hidden applications as the research teams associated with the market across the globe is packed with enough data to drive the future prospects of the drug delivery system.
Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028 Report Overview:
- Controlled Release Drug Delivery Market Opportunity: > 90 Billion By 2028
- Global & Regional Market Forecast Till 2028
- Controlled Release Drug Clinical Pipeline Insight By Phase, Indication, Company, Country & Drug Class
- Comprehensive Clinical insight On More Than 200 Drug in Clinical Trials
- Comprehensive Clinical insight On More Than 150 Drug Available in market
- Drug Pricing, Patent & Dosage Insight By indication: Alzheimer’s, Parkinson’s, Schizophrenia , Chronic Pain, Multiple Sclerosis, Diabetes Mellitus, Hypertension & Angina Pectoris
Controlled release drug mechanism has provided novel delivery platform that can be optimized, thus resulting in the generation of a robust, strong and impressive pipeline of the controlled release drugs for the broad-spectrum diseases like cancer, infectious diseases, autoimmune diseases, inflammatory diseases and neurological affections. Already available controlled release drugs categorized under tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) or glucagon-like peptide-1 (GLP-1) analogues for diabetes have been completely revolutionizing the pharmaceutical market by increasing the survival rate of the patients and who have been receiving major toxicity and side-effects due to unwanted concentration of the drug inside the body.
The efforts involved in the development of the market and associated parameters have helped the market to deliver promising results, thus, making the controlled release mechanism as one of the widely accepted and appreciated drug delivery system. Drug developers are now adopting to controlled release mechanism of delivering the drug in order to push the sales of the new as well existing drugs for key indications. Also, diminished side effects, reduced toxicity and maximum precision are some of the factors with which controlled release drugs are getting continuous level of acceptance from the researchers as well as the patients. It is estimated that the advent of control release technology as an important supportive technology in therapeutics sector is shaping the market towards success which researchers and patients were in need for a long period of time.
As per Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028 report findings, the arrival of the respective drug delivery market has brought a fundamental change and transformation shift in the pharmaceutical sector as it has slated every limits that were there in the previous markets which were leading to the development of unwanted side-effects in the patients. The market is also attracting several novel patients as the wide applications received by the older patients are expected to increase the bars of the markets with respect to advantages and benefits. Through the analysis of the market, it can be observed that development of safe as well as effective controlled release drugs by the researchers and the clinicians is estimated to provide the market specific pharmacotherapeutic regimens, leading to wide-adoption of the market. Furthermore, the robust clinical pipeline of the market and its impact on delivering the desired concentration of the drug is suggesting high-end future growth in every indication. It is believed that the market will soon explore the hidden applications as the research teams associated with the market across the globe is packed with enough data to drive the future prospects of the drug delivery system.
1. INTRODUCTION TO CONTROLLED DRUG DELIVERY
1.1 Novel Drug Delivery Systems
1.2 Preamble to Controlled Drug Delivery
1.3 Drug Delivery Technology
1.4 Fundamentals of Controlled Delivery
1.5 Basis for Controlled Drug Delivery
1.6 Controlled Drug Delivery Mechanism of Action
2. CONTROLLED DRUG DELIVERY CLASSIFICATION
2.1 By Delivery Systems
2.2 By Technology
2.3 By Routes of Delivery
2.4 Material Based Approaches for Controlled Drug Delivery
3. GLOBAL CONTROLLED DRUG MARKET OVERVIEW & RECENT TRENDS AT REGIONAL LEVEL
3.1 US
3.2 Europe
3.3 Japan
4. GLOBAL CONTROLLED RELEASE DRUG CLINICAL PIPELINE OVERVIEW
4.1 By Phase
4.2 By Company
4.3 By Country/Region
4.4 By Drug Class
4.5 By Indication
5. CONTROLLED RELEASE DRUGS FOR ALZHEIMER’S DISEASE - PRICING, PATENT & DOSAGE INSIGHT
5.1 Namzaric (Extended-Release)
5.2 Namenda XR (Extended – Release)
5.3 Razadyne ER (Extended – Release)
6. CONTROLLED RELEASE DRUGS FOR PARKINSON’S DISEASE - PRICING, PATENT & DOSAGE INSIGHT
6.1 Gocovri (Extended- Release)
6.2 Osmolex ER (Extended - Release)
7. CONTROLLED RELEASE DRUGS FOR SCHIZOPHRENIA - PRICING, PATENT & DOSAGE INSIGHT
7.1 Perseris (Extended – Release)
7.2 Invega (Extended – Release)
7.3 Invega Sustenna/Invega Trinza (Extended – Release)
7.4 Seroquel XR (Extended – Release)
7.5 Abilify Maintena (Extended – Release)
7.6 Aristada (Extended – Release)
8. CONTROLLED RELEASE DRUGS FOR CHRONIC PAIN - PRICING, PATENT & DOSAGE INSIGHT
8.1 Hysingla ER (Extended – Release)
8.2 Nucynta ER (Extended – Release)
8.3 Kadian (Extended – Release)
8.4 Xtampza ER (Extended – Release)
8.5 MS Contin (Extended – Release)
8.6 Embeda (Extended – Release)
9. CONTROLLED RELEASE DRUGS FOR MULTIPLE SCLEROSIS - PRICING, PATENT & DOSAGE INSIGHT
9.1 Ampyra (Extended – Release)
9.2 Tecfidera (Delayed – Release)
9.3 Rayos (Delayed – Release)
9.4 Vumerity (Delayed – Release)
10. CONTROLLED RELEASE DRUGS FOR DIABETES MELLITUS TYPE II - PRICING, PATENT & DOSAGE INSIGHT
10.1 Glumetza (Extended – Release)
10.2 Glucotrol XL (Extended – Release)
10.3 Fortamet (Extended – Release)
10.4 Glucophage XR (Extended – Release)
10.5 Bydureon (Extended – Release)
11. CONTROLLED RELEASE DRUGS FOR HYPERTENSION & ANGINA PECTORIS - PRICING, PATENT & DOSAGE INSIGHT
11.1 Procardia XL (Extended – Release)
11.2 Toprol XL (Extended – Release)
11.3 Adalat CC (Extended – Release)
11.4 Verelan PM (Extended – Release)
11.5 Plendil (Extended – Release)
11.6 Cardizem LA (Extended – Release)
12. GLOBAL CONTROLLED DRUG CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-I
12.5 Phase-I/II
12.6 Phase-II
12.7 Phase-II/III
12.8 Phase-III
12.9 Preregistration
12.10 Registered
13. MARKETED CONTROLLED DRUG CLINICAL INSIGHT BY COMPANY & INDICATION
14. GLOBAL CONTROLLED DRUG DELIVERY MARKET DYNAMICS
14.1 Market Drivers
14.2 Challenges to be Resolved
15. GLOBAL CONTROLLED DRUG DELIVERY MARKET FUTURE OUTLOOK
16. COMPETITIVE LANDSCAPE
16.1 AbbVie
16.2 Adare Pharma Solutions
16.3 Assertio Therapeutics
16.4 Astellas Pharma
16.5 AstraZeneca
16.6 Bristol-Myers Squibb
16.7 GlaxoSmithKline
16.8 Pfizer
16.9 Sanofi
16.10 Supernus Pharmaceuticals
16.11 Takeda
1.1 Novel Drug Delivery Systems
1.2 Preamble to Controlled Drug Delivery
1.3 Drug Delivery Technology
1.4 Fundamentals of Controlled Delivery
1.5 Basis for Controlled Drug Delivery
1.6 Controlled Drug Delivery Mechanism of Action
2. CONTROLLED DRUG DELIVERY CLASSIFICATION
2.1 By Delivery Systems
2.2 By Technology
2.3 By Routes of Delivery
2.4 Material Based Approaches for Controlled Drug Delivery
3. GLOBAL CONTROLLED DRUG MARKET OVERVIEW & RECENT TRENDS AT REGIONAL LEVEL
3.1 US
3.2 Europe
3.3 Japan
4. GLOBAL CONTROLLED RELEASE DRUG CLINICAL PIPELINE OVERVIEW
4.1 By Phase
4.2 By Company
4.3 By Country/Region
4.4 By Drug Class
4.5 By Indication
5. CONTROLLED RELEASE DRUGS FOR ALZHEIMER’S DISEASE - PRICING, PATENT & DOSAGE INSIGHT
5.1 Namzaric (Extended-Release)
5.2 Namenda XR (Extended – Release)
5.3 Razadyne ER (Extended – Release)
6. CONTROLLED RELEASE DRUGS FOR PARKINSON’S DISEASE - PRICING, PATENT & DOSAGE INSIGHT
6.1 Gocovri (Extended- Release)
6.2 Osmolex ER (Extended - Release)
7. CONTROLLED RELEASE DRUGS FOR SCHIZOPHRENIA - PRICING, PATENT & DOSAGE INSIGHT
7.1 Perseris (Extended – Release)
7.2 Invega (Extended – Release)
7.3 Invega Sustenna/Invega Trinza (Extended – Release)
7.4 Seroquel XR (Extended – Release)
7.5 Abilify Maintena (Extended – Release)
7.6 Aristada (Extended – Release)
8. CONTROLLED RELEASE DRUGS FOR CHRONIC PAIN - PRICING, PATENT & DOSAGE INSIGHT
8.1 Hysingla ER (Extended – Release)
8.2 Nucynta ER (Extended – Release)
8.3 Kadian (Extended – Release)
8.4 Xtampza ER (Extended – Release)
8.5 MS Contin (Extended – Release)
8.6 Embeda (Extended – Release)
9. CONTROLLED RELEASE DRUGS FOR MULTIPLE SCLEROSIS - PRICING, PATENT & DOSAGE INSIGHT
9.1 Ampyra (Extended – Release)
9.2 Tecfidera (Delayed – Release)
9.3 Rayos (Delayed – Release)
9.4 Vumerity (Delayed – Release)
10. CONTROLLED RELEASE DRUGS FOR DIABETES MELLITUS TYPE II - PRICING, PATENT & DOSAGE INSIGHT
10.1 Glumetza (Extended – Release)
10.2 Glucotrol XL (Extended – Release)
10.3 Fortamet (Extended – Release)
10.4 Glucophage XR (Extended – Release)
10.5 Bydureon (Extended – Release)
11. CONTROLLED RELEASE DRUGS FOR HYPERTENSION & ANGINA PECTORIS - PRICING, PATENT & DOSAGE INSIGHT
11.1 Procardia XL (Extended – Release)
11.2 Toprol XL (Extended – Release)
11.3 Adalat CC (Extended – Release)
11.4 Verelan PM (Extended – Release)
11.5 Plendil (Extended – Release)
11.6 Cardizem LA (Extended – Release)
12. GLOBAL CONTROLLED DRUG CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-I
12.5 Phase-I/II
12.6 Phase-II
12.7 Phase-II/III
12.8 Phase-III
12.9 Preregistration
12.10 Registered
13. MARKETED CONTROLLED DRUG CLINICAL INSIGHT BY COMPANY & INDICATION
14. GLOBAL CONTROLLED DRUG DELIVERY MARKET DYNAMICS
14.1 Market Drivers
14.2 Challenges to be Resolved
15. GLOBAL CONTROLLED DRUG DELIVERY MARKET FUTURE OUTLOOK
16. COMPETITIVE LANDSCAPE
16.1 AbbVie
16.2 Adare Pharma Solutions
16.3 Assertio Therapeutics
16.4 Astellas Pharma
16.5 AstraZeneca
16.6 Bristol-Myers Squibb
16.7 GlaxoSmithKline
16.8 Pfizer
16.9 Sanofi
16.10 Supernus Pharmaceuticals
16.11 Takeda
LIST OF FIGURES
Figure 1-1: Limitations of the Conventional Drug Delivery Systems
Figure 1-2: Diversification of the Novel Drug Delivery Platforms
Figure 1-3: History of Drug Delivery Technology from First Generation till Third
Generation
Figure 1-4: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 1-5: Demonstration of the Targeted & Non-Targeted Drug Delivery
Figure 1-6: Controlled Drug Release is by Zero Order Mechanism
Figure 1-7: Differentiation of the Two Forms of the Diffusion Controlled
Mechanisms
Figure 1-8: Mechanism of Encapsulation Dissolution Controlled System
Figure 1-9: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 1-10: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 2-1: Plasma Concentration v/s Time Profile in Conventional & Controlled
Release
Figure 2-2: Comparison of Varied Modified Drug Release Systems
Figure 2-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 2-4: Classification Based Over the Technicality Erudition
Figure 2-5: Structural Differentiation among Varied Classified Drug Delivery
Systems
Figure 2-6: Classification Based over the Route of Administration
Figure 2-7: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 2-8: Varied Nanostructures Available for the Nanoparticulate Delivery
System
Figure 3-1: US –Controlled Release Market Size (US$ Billion), 2020 - 2028
Figure 3-2: US – Population Above & Below 65 Years of Age (%), 2021
Figure 3-3: US – Share in Global Controlled Release Drug Market (%), 2021
Figure 3-4: Europe –Controlled Release Drug Delivery Market Size (US$ Billion),
2020 - 2028
Figure 3-5: Europe – Share in Global Controlled Release Drug Market (%), 2021
Figure 3-6: European Union – Population Above & Below 65 Years (%), 2021
Figure 3-7: European Union – Estimated Cases of Dementia, 2030 & 2050
Figure 3-8: Japan – Population Above & Below 65 Years (%), 2021
Figure 3-9: Japan – Dementia Cases (Million), 2018 & 2025
Figure 4-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2022
till 2028
Figure 4-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number),
2022 till 2028
Figure 4-3: Global - Controlled Release Drug Clinical Pipeline by Company
(Number), 2022 till 2028
Figure 4-4: Global - Controlled Release Drug Clinical Pipeline by Country/Region
(Number), 2022 till 2028
Figure 4-5: Global - Controlled Release Drug Clinical Pipeline by Drug Class
(Number), 2022 till 2028
Figure 4-6: Global - Controlled Release Drug Clinical Pipeline by indication
(Number), 2022 till 2028
Figure 5-1: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-7
mg, 10 mg-14 mg, 10 mg-21 mg, 10 mg–28 mg (US$), October’2022
Figure 5-2: Namenda XR – Available Dosage Strengths (mg), October 2022
Figure 5-3: Namenda XR – Price of 30 Oral Capsules, Extended Release of Dosage
mg, 14 mg, 21 mg, 28 mg (US$), October 2022
Figure 5-4: Namenda XR – Price of 90 Oral Capsules, Release of Dosage 14 mg,
mg (US$), October 2022
Figure 5-5: Razadyne XR – Available Dosage Strengths (mg), October 2022
Figure 5-6: Razadyne ER – Price of Oral Capsule, Extended Release of Dosage 8 mg,
16 mg, 24 mg (US$), October’2022
Figure 6-1: Gocovri XR – Available Dosage Strengths (mg), October 2022
Figure 6-2: Gocovri – Price of Oral Capsule, Extended Release of Dosage 68.5 mg,
137 mg (US$), October’2022
Figure 6-3: Global - Gocovri Quarterly Sales (US$ Million), H1’2022
Figure 6-4: Osmolex ER – Available Dosage Strengths (mg), October 2022
Figure 6-5: Osmolex – Price of Oral Capsule, Extended Release of Dosage 129 mg
(US$), October’2022
Figure 6-6: Osmolex – Price of Oral Capsule, Extended Release of Dosage 129 mg-
193 mg (US$), October’2022
Figure 6-7: Osmolex – Price of Oral Capsule, Extended Release of Dosage 193 mg
(US$), October’2022
Figure 7-1: Perseris: Available Dosage Strengths (mg)
Figure 7-2: Perseris: Price of 1 Subcutaneous Powder for Injection, Extended
Release (US$) October’2022
Figure 7-3: Perseris: Global Annual Sales (US$ Millions), 2019-2022*
Figure 7-4: Perseris: Global Quarterly Sales (US$ Millions), 2022
Figure 7-5: Invega – Available Dosage Strengths (mg)
Figure 7-6: Invega – Price of Oral Tablets, Extended Release of Dosage 1.5 mg,
mg, 6mg (US$), October’2022
Figure 7-7: Invega – Price of Oral Tablets, Extended Release of Dosage 9 mg (US$),
October’2022
Figure 7-8: Invega Sustenna – Available Dosage Strengths (mg)
Figure 7-9: Invega Trinza – Available Dosage Strengths (mg)
Figure 7-10: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 39 mg (US$), October’2022
Figure 7-11: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 78 mg (US$), October’2022
Figure 7-12: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 117 mg (US$), October’2022
Figure 7-13: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 156 mg (US$), October’2022
Figure 7-14: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 234 mg (US$), October’2022
Figure 7-15: Invega Trinza – Price of Intramuscular Suspension Extended Release
273 mg (US$), October’2022
Figure 7-16: Invega Trinza – Price of Intramuscular Suspension Extended Release
410 mg (US$), October’2022
Figure 7-17: Invega Trinza – Price of Intramuscular Suspension Extended Release
546 mg (US$), October’2022
Figure 7-18: Invega Trinza – Price of Intramuscular Suspension Extended Release
819 mg (US$), October’2022
Figure 7-19: US - Invega Sustenna/ Invega Trinza Annual Global Sales (US$ Million),
2018-2022*
Figure 7-20: US - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 – Q3 (US$
Million), 2022
Figure 7-21: Seroquel XR – Available Dosage Strengths (mg)
Figure 7-22: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-23: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-24: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-25: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-26: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-27: Global - Seroquel XR Total Annual Sales (US$ Million), 2017 - 2021
Figure 7-28: Global - Seroquel XR Quarterly Sales Q1 – Q4 (US$ Million), 2021
Figure 7-29: Abilify Maintena – Available Dosage Strengths (mg)
Figure 7-30: Abilify Maintena – Price of Intramuscular Powder for Injection,
Extended Release for Dosage 300 mg & 400 mg (US$), October’2022
Figure 7-31: Abilify Maintena – Global Annual Sales (US$ Million), 2019-2021
Figure 7-32: Aristada – Available Dosage Strengths (mg)
Figure 7-33: Aristada – Price of Intramuscular Suspension, Extended Release of
Dosage 441 mg (US$), October’2022
Figure 7-34: Aristada – Price of Intramuscular Suspension, Extended Release of
Dosage 662 mg (US$), October’2022
Figure 7-35: Aristada – Price of Intramuscular Suspension, Extended Release of
Dosage 882 mg (US$), October’2022
Figure 7-36: Aristada – Price of Intramuscular Suspension, Extended Release of
Dosage 1064 mg (US$), October’2022
Figure 7-37: Aristada - Global Annual Sales (US$ Million), 2018-2022*
Figure 7-38: Aristada - Quarterly Global Sales (US$ Million), H1’2022
Figure 8-1: Hysingla ER – Available Dosage Strengths (mg)
Figure 8-2: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 20 mg
(US$), October’2022
Figure 8-3: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 30 mg
(US$), October’2022
Figure 8-4: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 40 mg (US$), October’2022
Figure 8-5: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 60 mg (US$), October’2022
Figure 8-6: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 80 mg (US$), October’2022
Figure 8-7: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 100 mg (US$), October’2022
Figure 8-8: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 120 mg (US$), October’2022
Figure 8-9: Nucynta ER – Available Dosage Strengths (mg)
Figure 8-10: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 50 mg (US$), October’2022
Figure 8-11: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 100 mg (US$), October’2022
Figure 8-12: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 150 mg (US$), October’2022
Figure 8-13: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 200 mg (US$), October’2022
Figure 8-14: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 250 mg (US$), October’2022
Figure 8-15: Nucynta ER - Global Annual Sales (US$ Million), 2018-2022*
Figure 8-16: Nucynta ER - Global Quarterly Sales (US$ Million), H1’2022
Figure 8-17: Kadian – Available Dosage Strengths (mg)
Figure 8-18: Kadian – Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr (US$), October’2022
Figure 8-19: Kadian – Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr (US$), October’2022
Figure 8-20: Kadian – Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US$), October’2022
Figure 8-21: Kadian – Price of Oral Capsules, Extended Release of Dosage 80 mg/12 to 24 hr (US$), October’2022
Figure 8-22: Kadian – Price of Oral Capsules, Extended Release of Dosage 100 mg/12 to 24 hr (US$), October’2022
Figure 8-23: Kadian – Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr (US$), October’2022
Figure 8-24: Xtampza ER – Available Dosage Strengths (mg)
Figure 8-25: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 9 mg (US$), October’2022
Figure 8-26: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 13.5 mg (US$), October’2022
Figure 8-27: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 18 mg (US$), October’2022
Figure 8-28: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 27 mg (US$), October’2022
Figure 8-29: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 36 mg (US$), October’2022
Figure 8-30: Xtampza ER – Annual Global Sales (US$ Million), 2018-2022*
Figure 8-31: Xtampza ER - Quarterly Global Sales (US$ Million), H1’2022
Figure 8-32: MS Contin – Available Dosage Strengths (mg)
Figure 8-33: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US$), October’2022
Figure 8-34: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 30 mg/ 8 to 12 hr (US$), October’2022
Figure 8-35: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 60 mg/ 8 to 12 hr (US$), October’2022
Figure 8-36: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 100 mg/ 8 to 12 hr (US$), October’2022
Figure 8-37: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 200 mg/ 8 to 12 hr (US$), October’2022
Figure 8-38: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 20 mg-0.8 mg (US$), October’2022
Figure 8-39: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 30 mg-1.2mg (US$), October’2022
Figure 8-40: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 50 mg-2mg (US$), October’2022
Figure 8-41: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 60 mg-2.4 mg (US$), October’2022
Figure 8-42: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 80 mg-3.2mg (US$), October’2022
Figure 8-43: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 100 mg-4 mg (US$), October’2022
Figure 9-1: Ampyra – Price of Oral Tablet, Extended Release of Dosage 10 mg (US$), October’2022
Figure 9-2: Ampyra - Global Annual Sales (US$ Million), 2018-2022*
Figure 9-3: Ampyra - Global Quarterly Sales (US$ Million), H1’2022
Figure 9-4: Tecfidera – Available Dosage Strengths (mg)
Figure 9-5: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US$), October’2022
Figure 9-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 240 mg (US$), October’2022
Figure 9-7: Tecdifera Global Annual Sales (US$ Million), 2018-2022*
Figure 9-8: Global – Tecdifera Quarterly Sales (US$ Million), H1’2022
Figure 9-9: Rayos – Available Dosage Strengths (mg)
Figure 9-10: Rayos - Price of Oral Tablet, Delayed Release of All Dosages (US$), October’2022
Figure 9-11: Rayos - Global Annual Sales (US$ Million), 2018-2022*
Figure 9-12: Rayos - Global Quarterly Sales (US$ Million), H1’2022
Figure 9-13: Vumerity – Price of 231 mg Bottle, Delayed Release (US$), October’2022
Figure 9-14: Vumerity - Global Annual Sales (US$ Million), 2019-2022*
Figure 9-15: Vumerity - Global Quarterly Sales (US$ Million), H1’2022
Figure 10-1: Glumetza – Available Dosage Strengths (mg)
Figure 10-2: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 500 mg (US$), October’2022
Figure 10-3: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US$), October’2022
Figure 10-4: Glucotrol XL – Available Dosage Strengths (mg)
Figure 10-5: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 2.5 mg (US$), October’2022
Figure 10-6: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), October’2022
Figure 10-7: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), October’2022
Figure 10-8: Fortamet – Available Dosage Strengths (mg)
Figure 10-9: Global – Price of Fortamet Oral Tablets, Extended Release (US$), October’2022
Figure 10-10: Glucophage XR – Available Dosage Strengths (mg)
Figure 10-11: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 500 mg (US$), October’2022
Figure 10-12: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 750 mg (US$), October’2022
Figure 10-13: Global – Price of Bydureon Powder for Injection of Dosage 2 mg (US$), October’2022
Figure 10-14: Bydureon – Global Annual Sales (US$ Million), 2018-2022
Figure 10-15: Bydureon - Global Quarterly Sales (US$ Million), H1’2022
Figure 11-1: Procardia XL – Available Dosage Strengths (mg)
Figure 11-2: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), October’2022
Figure 11-3: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), October’2022
Figure 11-4: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 90 mg (US$), October’2022
Figure 11-5: Toprol XL – Available Dosage Strengths
Figure 11-6: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), October’2022
Figure 11-7: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), October’2022
Figure 11-8: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), October’2022
Figure 11-9: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), October’2022
Figure 11-10: Adalat CC – Available Dosage Strengths (mg)
Figure 11-11: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), October’2022
Figure 11-12: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), October’2022
Figure 11-13: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 90 mg (US$), October’2022
Figure 11-14: Verelan PM – Available Dosage Strengths (mg)
Figure 11-15: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US$), October’2022
Figure 11-16: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US$), October’2022
Figure 11-17: Plendil – Available Dosage Strengths (mg)
Figure 11-18: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 2.5 mg (US$), October’2022
Figure 11-19: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 5 mg (US$), October’2022
Figure 11-20: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 10 mg (US$), October’2022
Figure 11-21: Cardizem LA – Available Dosage Strengths (mg)
Figure 11-22: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), October’2022
Figure 11-23: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), October’2022
Figure 11-24: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), October’2022
Figure 11-25: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), October’2022
Figure 11-26: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), October’2022
Figure 11-27: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), October’2022
Figure 14-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 14-2: Major Challenges Faced by Controlled Drug Delivery System
Figure 15-1: Global – Controlled Release Drug Delivery Market Size (US$ Billion), 2020 – 2028
Figure 1-1: Limitations of the Conventional Drug Delivery Systems
Figure 1-2: Diversification of the Novel Drug Delivery Platforms
Figure 1-3: History of Drug Delivery Technology from First Generation till Third
Generation
Figure 1-4: Barriers to be Overcome by the Third Generation Drug Delivery System
Figure 1-5: Demonstration of the Targeted & Non-Targeted Drug Delivery
Figure 1-6: Controlled Drug Release is by Zero Order Mechanism
Figure 1-7: Differentiation of the Two Forms of the Diffusion Controlled
Mechanisms
Figure 1-8: Mechanism of Encapsulation Dissolution Controlled System
Figure 1-9: Osmotic Release of the Drug Delivery with the Controlled Mechanism
Figure 1-10: Illustration of Erosion Mechanisms Found in Matrix Systems
Figure 2-1: Plasma Concentration v/s Time Profile in Conventional & Controlled
Release
Figure 2-2: Comparison of Varied Modified Drug Release Systems
Figure 2-3: Illustration of Mechanism of Pulsatile Drug Release in Pulsincap
Figure 2-4: Classification Based Over the Technicality Erudition
Figure 2-5: Structural Differentiation among Varied Classified Drug Delivery
Systems
Figure 2-6: Classification Based over the Route of Administration
Figure 2-7: Categorization of Polymeric Controlled Drug Delivery Devices
Figure 2-8: Varied Nanostructures Available for the Nanoparticulate Delivery
System
Figure 3-1: US –Controlled Release Market Size (US$ Billion), 2020 - 2028
Figure 3-2: US – Population Above & Below 65 Years of Age (%), 2021
Figure 3-3: US – Share in Global Controlled Release Drug Market (%), 2021
Figure 3-4: Europe –Controlled Release Drug Delivery Market Size (US$ Billion),
2020 - 2028
Figure 3-5: Europe – Share in Global Controlled Release Drug Market (%), 2021
Figure 3-6: European Union – Population Above & Below 65 Years (%), 2021
Figure 3-7: European Union – Estimated Cases of Dementia, 2030 & 2050
Figure 3-8: Japan – Population Above & Below 65 Years (%), 2021
Figure 3-9: Japan – Dementia Cases (Million), 2018 & 2025
Figure 4-1: Global - Controlled Release Drug Clinical Pipeline by Phase (%), 2022
till 2028
Figure 4-2: Global - Controlled Release Drug Clinical Pipeline by Phase (Number),
2022 till 2028
Figure 4-3: Global - Controlled Release Drug Clinical Pipeline by Company
(Number), 2022 till 2028
Figure 4-4: Global - Controlled Release Drug Clinical Pipeline by Country/Region
(Number), 2022 till 2028
Figure 4-5: Global - Controlled Release Drug Clinical Pipeline by Drug Class
(Number), 2022 till 2028
Figure 4-6: Global - Controlled Release Drug Clinical Pipeline by indication
(Number), 2022 till 2028
Figure 5-1: Namzaric – Price of Oral Capsule, Extended Release of Dosage 10 mg-7
mg, 10 mg-14 mg, 10 mg-21 mg, 10 mg–28 mg (US$), October’2022
Figure 5-2: Namenda XR – Available Dosage Strengths (mg), October 2022
Figure 5-3: Namenda XR – Price of 30 Oral Capsules, Extended Release of Dosage
mg, 14 mg, 21 mg, 28 mg (US$), October 2022
Figure 5-4: Namenda XR – Price of 90 Oral Capsules, Release of Dosage 14 mg,
mg (US$), October 2022
Figure 5-5: Razadyne XR – Available Dosage Strengths (mg), October 2022
Figure 5-6: Razadyne ER – Price of Oral Capsule, Extended Release of Dosage 8 mg,
16 mg, 24 mg (US$), October’2022
Figure 6-1: Gocovri XR – Available Dosage Strengths (mg), October 2022
Figure 6-2: Gocovri – Price of Oral Capsule, Extended Release of Dosage 68.5 mg,
137 mg (US$), October’2022
Figure 6-3: Global - Gocovri Quarterly Sales (US$ Million), H1’2022
Figure 6-4: Osmolex ER – Available Dosage Strengths (mg), October 2022
Figure 6-5: Osmolex – Price of Oral Capsule, Extended Release of Dosage 129 mg
(US$), October’2022
Figure 6-6: Osmolex – Price of Oral Capsule, Extended Release of Dosage 129 mg-
193 mg (US$), October’2022
Figure 6-7: Osmolex – Price of Oral Capsule, Extended Release of Dosage 193 mg
(US$), October’2022
Figure 7-1: Perseris: Available Dosage Strengths (mg)
Figure 7-2: Perseris: Price of 1 Subcutaneous Powder for Injection, Extended
Release (US$) October’2022
Figure 7-3: Perseris: Global Annual Sales (US$ Millions), 2019-2022*
Figure 7-4: Perseris: Global Quarterly Sales (US$ Millions), 2022
Figure 7-5: Invega – Available Dosage Strengths (mg)
Figure 7-6: Invega – Price of Oral Tablets, Extended Release of Dosage 1.5 mg,
mg, 6mg (US$), October’2022
Figure 7-7: Invega – Price of Oral Tablets, Extended Release of Dosage 9 mg (US$),
October’2022
Figure 7-8: Invega Sustenna – Available Dosage Strengths (mg)
Figure 7-9: Invega Trinza – Available Dosage Strengths (mg)
Figure 7-10: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 39 mg (US$), October’2022
Figure 7-11: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 78 mg (US$), October’2022
Figure 7-12: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 117 mg (US$), October’2022
Figure 7-13: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 156 mg (US$), October’2022
Figure 7-14: Invega Sustenna – Price of Intramuscular Suspension, Extended
Release of Dosage 234 mg (US$), October’2022
Figure 7-15: Invega Trinza – Price of Intramuscular Suspension Extended Release
273 mg (US$), October’2022
Figure 7-16: Invega Trinza – Price of Intramuscular Suspension Extended Release
410 mg (US$), October’2022
Figure 7-17: Invega Trinza – Price of Intramuscular Suspension Extended Release
546 mg (US$), October’2022
Figure 7-18: Invega Trinza – Price of Intramuscular Suspension Extended Release
819 mg (US$), October’2022
Figure 7-19: US - Invega Sustenna/ Invega Trinza Annual Global Sales (US$ Million),
2018-2022*
Figure 7-20: US - Invega Sustenna/ Invega Trinza Quarterly Sales Q1 – Q3 (US$
Million), 2022
Figure 7-21: Seroquel XR – Available Dosage Strengths (mg)
Figure 7-22: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-23: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-24: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-25: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-26: Seroquel XR – Price of Oral Tablets, Extended Release of Dosage
mg (US$), October’2022
Figure 7-27: Global - Seroquel XR Total Annual Sales (US$ Million), 2017 - 2021
Figure 7-28: Global - Seroquel XR Quarterly Sales Q1 – Q4 (US$ Million), 2021
Figure 7-29: Abilify Maintena – Available Dosage Strengths (mg)
Figure 7-30: Abilify Maintena – Price of Intramuscular Powder for Injection,
Extended Release for Dosage 300 mg & 400 mg (US$), October’2022
Figure 7-31: Abilify Maintena – Global Annual Sales (US$ Million), 2019-2021
Figure 7-32: Aristada – Available Dosage Strengths (mg)
Figure 7-33: Aristada – Price of Intramuscular Suspension, Extended Release of
Dosage 441 mg (US$), October’2022
Figure 7-34: Aristada – Price of Intramuscular Suspension, Extended Release of
Dosage 662 mg (US$), October’2022
Figure 7-35: Aristada – Price of Intramuscular Suspension, Extended Release of
Dosage 882 mg (US$), October’2022
Figure 7-36: Aristada – Price of Intramuscular Suspension, Extended Release of
Dosage 1064 mg (US$), October’2022
Figure 7-37: Aristada - Global Annual Sales (US$ Million), 2018-2022*
Figure 7-38: Aristada - Quarterly Global Sales (US$ Million), H1’2022
Figure 8-1: Hysingla ER – Available Dosage Strengths (mg)
Figure 8-2: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 20 mg
(US$), October’2022
Figure 8-3: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 30 mg
(US$), October’2022
Figure 8-4: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 40 mg (US$), October’2022
Figure 8-5: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 60 mg (US$), October’2022
Figure 8-6: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 80 mg (US$), October’2022
Figure 8-7: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 100 mg (US$), October’2022
Figure 8-8: Hysingla ER – Price of Oral Tablet, Extended Release of Dosage 120 mg (US$), October’2022
Figure 8-9: Nucynta ER – Available Dosage Strengths (mg)
Figure 8-10: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 50 mg (US$), October’2022
Figure 8-11: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 100 mg (US$), October’2022
Figure 8-12: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 150 mg (US$), October’2022
Figure 8-13: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 200 mg (US$), October’2022
Figure 8-14: Global – Price of Nucynta ER Oral Tablets, Extended Release of Dosage 250 mg (US$), October’2022
Figure 8-15: Nucynta ER - Global Annual Sales (US$ Million), 2018-2022*
Figure 8-16: Nucynta ER - Global Quarterly Sales (US$ Million), H1’2022
Figure 8-17: Kadian – Available Dosage Strengths (mg)
Figure 8-18: Kadian – Price of Oral Capsules, Extended Release of Dosage 10 mg/12 to 24 hr (US$), October’2022
Figure 8-19: Kadian – Price of Oral Capsules, Extended Release of Dosage 50 mg/12 to 24 hr (US$), October’2022
Figure 8-20: Kadian – Price of Oral Capsules, Extended Release of Dosage 60 mg/12 to 24 hr (US$), October’2022
Figure 8-21: Kadian – Price of Oral Capsules, Extended Release of Dosage 80 mg/12 to 24 hr (US$), October’2022
Figure 8-22: Kadian – Price of Oral Capsules, Extended Release of Dosage 100 mg/12 to 24 hr (US$), October’2022
Figure 8-23: Kadian – Price of Oral Capsules, Extended Release of Dosage 200 mg/12 to 24 hr (US$), October’2022
Figure 8-24: Xtampza ER – Available Dosage Strengths (mg)
Figure 8-25: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 9 mg (US$), October’2022
Figure 8-26: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 13.5 mg (US$), October’2022
Figure 8-27: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 18 mg (US$), October’2022
Figure 8-28: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 27 mg (US$), October’2022
Figure 8-29: Global – Price of Xtampza ER Oral Capsules, Extended Release of Dosage 36 mg (US$), October’2022
Figure 8-30: Xtampza ER – Annual Global Sales (US$ Million), 2018-2022*
Figure 8-31: Xtampza ER - Quarterly Global Sales (US$ Million), H1’2022
Figure 8-32: MS Contin – Available Dosage Strengths (mg)
Figure 8-33: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 15 mg/ 8 to 12 hr (US$), October’2022
Figure 8-34: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 30 mg/ 8 to 12 hr (US$), October’2022
Figure 8-35: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 60 mg/ 8 to 12 hr (US$), October’2022
Figure 8-36: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 100 mg/ 8 to 12 hr (US$), October’2022
Figure 8-37: Global – Price of MS Contin Oral Tablet, Extended Release of Dosage 200 mg/ 8 to 12 hr (US$), October’2022
Figure 8-38: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 20 mg-0.8 mg (US$), October’2022
Figure 8-39: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 30 mg-1.2mg (US$), October’2022
Figure 8-40: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 50 mg-2mg (US$), October’2022
Figure 8-41: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 60 mg-2.4 mg (US$), October’2022
Figure 8-42: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 80 mg-3.2mg (US$), October’2022
Figure 8-43: Global – Price of Embeda Oral Capsules, Extended Release of Dosage 100 mg-4 mg (US$), October’2022
Figure 9-1: Ampyra – Price of Oral Tablet, Extended Release of Dosage 10 mg (US$), October’2022
Figure 9-2: Ampyra - Global Annual Sales (US$ Million), 2018-2022*
Figure 9-3: Ampyra - Global Quarterly Sales (US$ Million), H1’2022
Figure 9-4: Tecfidera – Available Dosage Strengths (mg)
Figure 9-5: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 120 mg (US$), October’2022
Figure 9-6: Tecfidera - Price of Oral Capsule, Delayed Release of Dosage 240 mg (US$), October’2022
Figure 9-7: Tecdifera Global Annual Sales (US$ Million), 2018-2022*
Figure 9-8: Global – Tecdifera Quarterly Sales (US$ Million), H1’2022
Figure 9-9: Rayos – Available Dosage Strengths (mg)
Figure 9-10: Rayos - Price of Oral Tablet, Delayed Release of All Dosages (US$), October’2022
Figure 9-11: Rayos - Global Annual Sales (US$ Million), 2018-2022*
Figure 9-12: Rayos - Global Quarterly Sales (US$ Million), H1’2022
Figure 9-13: Vumerity – Price of 231 mg Bottle, Delayed Release (US$), October’2022
Figure 9-14: Vumerity - Global Annual Sales (US$ Million), 2019-2022*
Figure 9-15: Vumerity - Global Quarterly Sales (US$ Million), H1’2022
Figure 10-1: Glumetza – Available Dosage Strengths (mg)
Figure 10-2: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 500 mg (US$), October’2022
Figure 10-3: Global – Price of Glumetza Oral Tablets, Extended Release of Dosage 1000 mg (US$), October’2022
Figure 10-4: Glucotrol XL – Available Dosage Strengths (mg)
Figure 10-5: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 2.5 mg (US$), October’2022
Figure 10-6: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), October’2022
Figure 10-7: Global – Price of Glucotrol XL Oral Tablets Extended Release of Dosage 5 mg (US$), October’2022
Figure 10-8: Fortamet – Available Dosage Strengths (mg)
Figure 10-9: Global – Price of Fortamet Oral Tablets, Extended Release (US$), October’2022
Figure 10-10: Glucophage XR – Available Dosage Strengths (mg)
Figure 10-11: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 500 mg (US$), October’2022
Figure 10-12: Global – Price of Glucophage XR Oral Tablet, Extended Release of Dosage 750 mg (US$), October’2022
Figure 10-13: Global – Price of Bydureon Powder for Injection of Dosage 2 mg (US$), October’2022
Figure 10-14: Bydureon – Global Annual Sales (US$ Million), 2018-2022
Figure 10-15: Bydureon - Global Quarterly Sales (US$ Million), H1’2022
Figure 11-1: Procardia XL – Available Dosage Strengths (mg)
Figure 11-2: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 30 mg (US$), October’2022
Figure 11-3: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 60 mg (US$), October’2022
Figure 11-4: Global – Price of Procardia XL Oral Tablet, Extended Release of Dosage 90 mg (US$), October’2022
Figure 11-5: Toprol XL – Available Dosage Strengths
Figure 11-6: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 25 mg (US$), October’2022
Figure 11-7: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 50 mg (US$), October’2022
Figure 11-8: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 100 mg (US$), October’2022
Figure 11-9: Global – Price of Toprol XL Oral Tablet, Extended Release of Dosage 200 mg (US$), October’2022
Figure 11-10: Adalat CC – Available Dosage Strengths (mg)
Figure 11-11: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 30 mg (US$), October’2022
Figure 11-12: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 60 mg (US$), October’2022
Figure 11-13: Global – Price of Adalat CC Oral Tablet Extended Release of Dosage 90 mg (US$), October’2022
Figure 11-14: Verelan PM – Available Dosage Strengths (mg)
Figure 11-15: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 200 mg/24 hr (US$), October’2022
Figure 11-16: Global – Price of Verelan PM Oral Capsule, Extended Release of Dosage 300 mg/24 hr (US$), October’2022
Figure 11-17: Plendil – Available Dosage Strengths (mg)
Figure 11-18: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 2.5 mg (US$), October’2022
Figure 11-19: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 5 mg (US$), October’2022
Figure 11-20: Global – Price of Plendil Oral Tablet, Extended Release of Dosage 10 mg (US$), October’2022
Figure 11-21: Cardizem LA – Available Dosage Strengths (mg)
Figure 11-22: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 120 mg/24 hr (US$), October’2022
Figure 11-23: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 180 mg/24 hr (US$), October’2022
Figure 11-24: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 240 mg/24 hr (US$), October’2022
Figure 11-25: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 300 mg/24 hr (US$), October’2022
Figure 11-26: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 360 mg/24 hr (US$), October’2022
Figure 11-27: Global – Price of Cardizem LA Oral Tablet, Extended Release of Dosage 420 mg/24 hr (US$), October’2022
Figure 14-1: Accelerative Parameters of Controlled Drug Delivery Systems
Figure 14-2: Major Challenges Faced by Controlled Drug Delivery System
Figure 15-1: Global – Controlled Release Drug Delivery Market Size (US$ Billion), 2020 – 2028
